Science

Concurrent PIK3CA mutant drives cachexia through inflammatory signaling in EGFR mutant lung cancer

lung cancer/X

Jan 25, 2025, 16:47

Concurrent PIK3CA mutant drives cachexia through inflammatory signaling in EGFR mutant lung cancer

Amy C. Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, shared an article by Meiting Yue on LinkedIn:

“One of my ongoing frustrations as part of my participation in Cancer Grand Challenges Team CANCAN‘s work to uncover the causes of cancer cachexia has been the limitation of existing animal models that don’t reflect the realities of the patient population.

For example, we have been limited to a KRAS G12D driven lung cancer model. And while KRAS is a major driver of LC, I have been calling for additional models that reflect the diversity of the patient population.

This paper helps address that.

Thanks for sharing, Marcus Goncalves.”

Concurrent PIK3CA mutant drives cachexia through inflammatory signaling in EGFR mutant lung cancer.

Authors: Meiting Yue, et al.

Concurrent PIK3CA mutant drives cachexia through inflammatory signaling in EGFR mutant lung cancer

Amy C. Moore CANCAN cancer EGFR fight against cancer Global fight against cancer KRAS G12D Lung cancer LUNGevity Foundation Meiting Yue OncoDaily Oncology PIK3CA

No recurrences in MSS colorectal cancer with BOT/BAL neoadjuvant immunotherapy: NEST Trial updates from ASCOGI25

Agenus announced new data highlighting BOT/BAL across multiple lines of treatment in Colorectal Cancer

President Trump has announced U.S. Withdrawal from the World Health Organization

OncoDaily Acquires CancerWorld: A New Era in Oncology Media

FDA approved sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer